174 related articles for article (PubMed ID: 25696914)
1. Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy.
Kusumoto S; Tobinai K
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):576-83. PubMed ID: 25696914
[TBL] [Abstract][Full Text] [Related]
2. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study.
Tsai YF; Yang CI; Du JS; Lin MH; Tang SH; Wang HC; Cho SF; Liu YC; Su YC; Dai CY; Hsiao HH
PeerJ; 2019; 7():e7481. PubMed ID: 31565551
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study.
Marzo B; Vidal-Jordana A; Castilló J; Robles-Sanchez MA; Otero-Romero S; Tintore M; Montalban X; Buti M; Riveiro-Barciela M
J Neurol; 2024 Jan; 271(1):134-140. PubMed ID: 37695530
[TBL] [Abstract][Full Text] [Related]
4. Size Matters! Anti-HBs Titer and HBV Reactivation During Anti-TNF Therapy.
Poola S; Kratzer M; Sewell K; Tillmann HL
Dig Dis Sci; 2023 Dec; 68(12):4511-4520. PubMed ID: 37891440
[TBL] [Abstract][Full Text] [Related]
5. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg
Kuo MH; Tseng CW; Lee CH; Tung CH; Tseng KC; Lai NS
Sci Rep; 2020 Feb; 10(1):2456. PubMed ID: 32051458
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus management to prevent reactivation after chemotherapy: a review.
Hwang JP; Vierling JM; Zelenetz AD; Lackey SC; Loomba R
Support Care Cancer; 2012 Nov; 20(11):2999-3008. PubMed ID: 22933131
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection.
Kotake T; Satake H; Okita Y; Hatachi Y; Hamada M; Omiya M; Yasui H; Hashida T; Kaihara S; Inokuma T; Tsuji A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):63-68. PubMed ID: 29984542
[TBL] [Abstract][Full Text] [Related]
8. Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients.
Liu H; He Z; Gui R; Guo J; Chen L; Zhong M; Li J; Cao L; Fan L
Br J Haematol; 2023 Nov; 203(4):571-580. PubMed ID: 37803485
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
Hong J; Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Sinn DH; Ahn MJ
Cancer; 2024 May; 130(9):1693-1701. PubMed ID: 38165808
[TBL] [Abstract][Full Text] [Related]
10. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
Kuo MH; Tseng CW; Ko PH; Wang ST; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
Liver Int; 2024 Feb; 44(2):497-507. PubMed ID: 38010984
[TBL] [Abstract][Full Text] [Related]
11. Case report: Recombinant human type II tumour necrosis factor receptor-antibody fusion protein induced occult hepatitis B virus reactivation leading to liver failure.
Qin Y; Zhou W; Zhou X; Li H
J Int Med Res; 2024 May; 52(5):3000605241252580. PubMed ID: 38760056
[TBL] [Abstract][Full Text] [Related]
12. Steady Decline of HBV DNA Load under NAs in Lymphoma Patients and a Higher Level of qAnti-HBc Predict HBV Reactivation.
Liu Y; Nuersulitan R; Zhang C; Huo N; Li J; Song Y; Zhu J; Liu W; Zhao H
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202030
[No Abstract] [Full Text] [Related]
13. Optimal timing of antiviral therapy for patients with malignant tumor who presented with hepatitis B reactivation during chemotherapy and/or immunosuppressive therapy.
Zou X; Guo L; Gu Y; Yang Z; Huang P; Liu T; Zhao J; Wu G
J Cancer; 2020; 11(12):3559-3566. PubMed ID: 32284752
[No Abstract] [Full Text] [Related]
14. Implementation of Guideline-Based HBV Reactivation Management in Patients with Chronic HBV Infections of HBsAg or Resolved HBV Infection Undergoing Immunosuppressive Therapy.
Tanaka Y; Nakamoto D; Piao Y; Mizutani H; Wakabayashi R; Saito Y; Kwon KM; Dickinson H
Infect Dis Ther; 2024 May; ():. PubMed ID: 38809367
[TBL] [Abstract][Full Text] [Related]
15. Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab.
Haider M; Flocco G; Lopez R; Carey W
BMJ Open; 2020 Dec; 10(12):e043672. PubMed ID: 33323450
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous reactivation of hepatitis B virus with multiple novel mutations in an elderly patient with resolved hepatitis B virus infection.
Sasaki T; Kakisaka K; Miyasaka A; Nishiya M; Yanagawa N; Kuroda H; Matsumoto T; Takahashi M; Okamoto H
Clin J Gastroenterol; 2024 May; ():. PubMed ID: 38748198
[TBL] [Abstract][Full Text] [Related]
17. Fulminant hepatitis in a hepatitis B surface antigen-positive patient with adult T-cell leukemia-lymphoma after mogamulizumab monotherapy.
Nakashima T; Kusumoto S; Ishida T; Kato C; Hagiwara S; Narita T; Masaki A; Ito A; Ri M; Komatsu H; Inagaki H; Tanaka Y; Iida S
Hepatol Res; 2024 May; ():. PubMed ID: 38770705
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency.
Hatano M; Mimura T; Shimada A; Noda M; Katayama S
Endocrinol Diabetes Metab; 2019 Jul; 2(3):e00071. PubMed ID: 31294085
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B reactivation after chemotherapy: two decades of clinical research.
Lau GK
Hepatol Int; 2008 Jun; 2(2):152-62. PubMed ID: 19669300
[TBL] [Abstract][Full Text] [Related]
20. The risk factors and clinical outcomes in hepatitis B seropositive and seronegative renal transplant patients.
Tsai YL; Chung MH; Lin NC; Chen CY; Lin YP; Tsai MT; Tsai HL; Chen YA; Ou SM; Chu CJ; Wu TH; Tsai CY
Am J Nephrol; 2024 Mar; ():. PubMed ID: 38498992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
